Last reviewed · How we verify

Ddavp — Competitive Intelligence Brief

Ddavp (DESMOPRESSIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Factor VIII Activator. Area: Metabolic.

marketed Factor VIII Activator Vasopressin V1b receptor Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

Ddavp (DESMOPRESSIN) — Ferring Pharms Inc.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ddavp TARGET DESMOPRESSIN Ferring Pharms Inc marketed Factor VIII Activator Vasopressin V1b receptor 1978-01-01
Minirin Minirin Hormozgan University of Medical Sciences marketed Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor
Argipressin Argipressin Kristina Svennerholm marketed Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Factor VIII Activator class)

  1. Ferring Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ddavp — Competitive Intelligence Brief. https://druglandscape.com/ci/desmopressin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: